Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19 : Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study
Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized patients with severe pneumonia requiring oxygen supply and followed up for 6 months after hospital discharge (see primary and secondary outcomes).Secondary objectivesTo describe pulmonary sequelae according to :the unit in which the patient was hospitalized,the maximum oxygen flow rate required during hospitalization,McCabe score,age,tobacco consumption,biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),number of days from onset of symptoms to hospitalization,co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild to moderate COPD/respiratory failure, overweight),concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, ACE inhibitors)specific drug treatments administered to treat COVID-19 infection,non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment) to manage respiratory disorders of COVID-19 infection.To assess the impact of factors of social inequality on the severity of COVID-19 infection.Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2 SARS infection will be seen in consultation at approximately 3 and 6 months after hospital discharge, as per standard practice..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 16. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 10, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 |
|---|
| Study ID: |
NCT04505631 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003481891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003481891 | ||
| 003 | DE-627 | ||
| 005 | 20230425192920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003481891 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04505631 | ||
| 035 | |a (UBBS_Klinische_Studien)GHR 1052 | ||
| 035 | |a (UBBS_Klinische_Studien)IDRCB 2020-A01089-30 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19 |b Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 10, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 | ||
| 520 | |a Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized patients with severe pneumonia requiring oxygen supply and followed up for 6 months after hospital discharge (see primary and secondary outcomes).Secondary objectivesTo describe pulmonary sequelae according to :the unit in which the patient was hospitalized,the maximum oxygen flow rate required during hospitalization,McCabe score,age,tobacco consumption,biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),number of days from onset of symptoms to hospitalization,co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild to moderate COPD/respiratory failure, overweight),concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, ACE inhibitors)specific drug treatments administered to treat COVID-19 infection,non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment) to manage respiratory disorders of COVID-19 infection.To assess the impact of factors of social inequality on the severity of COVID-19 infection.Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2 SARS infection will be seen in consultation at approximately 3 and 6 months after hospital discharge, as per standard practice. | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Dyspnea | |
| 650 | 4 | |a Medical Condition: Covid19, Dyspnea | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 16. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:16 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04505631 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 16 |c 12 | ||